MA22471A1 - Procede de production de vaccin - Google Patents

Procede de production de vaccin

Info

Publication number
MA22471A1
MA22471A1 MA22760A MA22760A MA22471A1 MA 22471 A1 MA22471 A1 MA 22471A1 MA 22760 A MA22760 A MA 22760A MA 22760 A MA22760 A MA 22760A MA 22471 A1 MA22471 A1 MA 22471A1
Authority
MA
Morocco
Prior art keywords
production process
vaccine production
vaccine
production
Prior art date
Application number
MA22760A
Other languages
English (en)
Inventor
Francotte M
Slaoui M
Prieels Jp
Nm-Jcg-Johnson
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA22471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of MA22471A1 publication Critical patent/MA22471A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA22760A 1991-03-21 1992-03-19 Procede de production de vaccin MA22471A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9105992A GB9105992D0 (en) 1991-03-21 1991-03-21 Vaccine

Publications (1)

Publication Number Publication Date
MA22471A1 true MA22471A1 (fr) 1992-10-01

Family

ID=10691946

Family Applications (1)

Application Number Title Priority Date Filing Date
MA22760A MA22471A1 (fr) 1991-03-21 1992-03-19 Procede de production de vaccin

Country Status (33)

Country Link
US (1) US6027730A (fr)
EP (1) EP0576478B2 (fr)
JP (1) JP3530526B2 (fr)
KR (1) KR100224329B1 (fr)
CN (2) CN1058191C (fr)
AP (1) AP298A (fr)
AT (1) ATE129160T1 (fr)
AU (1) AU650521B2 (fr)
BR (1) BR9205745A (fr)
CA (1) CA2106492C (fr)
CY (1) CY1936A (fr)
CZ (1) CZ280505B6 (fr)
DE (1) DE69205566T3 (fr)
DK (1) DK0576478T4 (fr)
ES (1) ES2081102T5 (fr)
FI (1) FI107881B (fr)
GB (1) GB9105992D0 (fr)
GR (1) GR3017884T3 (fr)
HU (1) HU218025B (fr)
IE (1) IE69560B1 (fr)
IL (1) IL101290A (fr)
MA (1) MA22471A1 (fr)
MX (1) MX9201245A (fr)
MY (1) MY110086A (fr)
NO (1) NO307499B1 (fr)
NZ (1) NZ242057A (fr)
PL (1) PL170059B1 (fr)
PT (1) PT100262B (fr)
SA (1) SA92120459B1 (fr)
SK (1) SK279190B6 (fr)
WO (1) WO1992016231A1 (fr)
YU (1) YU28392A (fr)
ZA (1) ZA922011B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
WO1994019013A1 (fr) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o
EP0689454B2 (fr) * 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
DE69426077T3 (de) * 1993-05-25 2004-09-02 Wyeth Holdings Corp. Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2197217T3 (es) * 1994-12-28 2004-01-01 University Of Kentucky Research Foundation Anticuerpo 3h1 monoclonal anti-id-murino.
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1104767A1 (fr) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Dérivés de mono- et disaccharides contenant esters d'acides gras et esters de sulfate
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
TW200700079A (en) 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CN103251940A (zh) 2005-12-22 2013-08-21 葛兰素史密丝克莱恩生物有限公司 疫苗
EP1998802A2 (fr) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Composition immunogène
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
HUE031051T2 (en) * 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8809047B2 (en) * 2009-12-21 2014-08-19 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
EP2683402B1 (fr) * 2011-03-11 2020-06-24 Turnstone Limited Partnership Méthode de vaccination faisant intervenir un inhibiteur d'histone désacétylase
EP3632463A1 (fr) 2011-04-08 2020-04-08 Immune Design Corp. Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
WO2013028738A1 (fr) 2011-08-22 2013-02-28 Nanobio Corporation Vaccin contre le virus de l'herpès simplex sous forme de nanoémulsion
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
DK2941269T3 (da) 2013-01-07 2021-01-11 Mucosal Vaccine Tech Llc Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner
EP2986303B1 (fr) 2013-04-18 2020-02-26 Immune Design Corp. Monothérapie par gla pour une utilisation dans le traitement du cancer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
WO2019152821A1 (fr) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Virus de l'herpès simplex 2 recombinant exprimant des antigènes de glycoprotéine b et d
CA3208643A1 (fr) 2021-01-18 2022-07-21 Conserv Bioscience Limited Compositions immunogenes de coronavirus, methodes et utilisations de celles-ci

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
DE3751772T2 (de) * 1986-10-20 1996-12-05 Chiron Corp Impfstoff zur behandlung von hsv
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
JP2955314B2 (ja) * 1988-10-27 1999-10-04 リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ Ｉｌ―２含有リポソーム免疫アジュバント
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
FI920131A0 (fi) * 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
CA2088246A1 (fr) * 1990-08-01 1992-02-02 Dennis J. O'callaghan Gene codant la glycoproteine d du virus herpetique equin de type i, son produit genique, et anticorps de cette glycoproteine et leurs utilisations
JP3005292B2 (ja) * 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのｖｐ１６のワクチン
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
US5196452A (en) * 1991-01-29 1993-03-23 Genelabs Incorporated Macrocyclic anti-viral compound and method
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
NZ253137A (en) * 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
WO1994019013A1 (fr) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o
EP0689454B2 (fr) * 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
DE69426077T3 (de) * 1993-05-25 2004-09-02 Wyeth Holdings Corp. Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus

Also Published As

Publication number Publication date
PT100262A (pt) 1993-06-30
CY1936A (en) 1992-03-17
EP0576478B2 (fr) 2001-04-18
HU9302645D0 (en) 1994-01-28
JP3530526B2 (ja) 2004-05-24
AU650521B2 (en) 1994-06-23
CN1101226C (zh) 2003-02-12
PL170059B1 (pl) 1996-10-31
JPH06505727A (ja) 1994-06-30
EP0576478B1 (fr) 1995-10-18
IL101290A (en) 1996-07-23
NO933343L (no) 1993-09-20
ES2081102T3 (es) 1996-02-16
BR9205745A (pt) 1994-10-18
SK94693A3 (en) 1994-05-11
HUT67052A (en) 1995-01-30
MY110086A (en) 1997-12-31
ATE129160T1 (de) 1995-11-15
NO307499B1 (no) 2000-04-17
KR100224329B1 (ko) 1999-10-15
SK279190B6 (sk) 1998-07-08
YU28392A (sh) 1994-11-15
IL101290A0 (en) 1992-11-15
DE69205566T3 (de) 2002-09-05
GB9105992D0 (en) 1991-05-08
ZA922011B (en) 1993-01-27
NO933343D0 (no) 1993-09-20
DE69205566D1 (en) 1995-11-23
FI107881B (fi) 2001-10-31
CA2106492A1 (fr) 1992-09-22
DE69205566T2 (de) 1996-04-18
CZ195893A3 (en) 1994-07-13
CN1065997A (zh) 1992-11-11
EP0576478A1 (fr) 1994-01-05
IE69560B1 (en) 1996-10-02
FI934134A0 (fi) 1993-09-21
HK1004525A1 (en) 1998-11-27
SA92120459B1 (ar) 2005-06-14
AP298A (en) 1994-01-14
CZ280505B6 (cs) 1996-02-14
NZ242057A (en) 1993-12-23
WO1992016231A1 (fr) 1992-10-01
DK0576478T4 (da) 2001-07-23
CN1058191C (zh) 2000-11-08
GR3017884T3 (en) 1996-01-31
MX9201245A (es) 1992-10-01
IE920881A1 (en) 1992-09-23
HU218025B (hu) 2000-05-28
AU1365792A (en) 1992-10-21
CA2106492C (fr) 2003-12-09
FI934134L (fi) 1993-09-21
CN1201692A (zh) 1998-12-16
AP9200368A0 (en) 1992-04-30
PT100262B (pt) 2001-05-31
US6027730A (en) 2000-02-22
DK0576478T3 (da) 1995-12-04
ES2081102T5 (es) 2001-09-01

Similar Documents

Publication Publication Date Title
MA22471A1 (fr) Procede de production de vaccin
MA22911A1 (fr) Procede de production de formulations de vaccins.
MA22894A1 (fr) Procede de preparation d'un vaccin.
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
MA22381A1 (fr) Procede de production de vaccins
MA22563A1 (fr) Procede de preparation de derives de tetrahydrocarbazole
NO180484C (no) Fremgangsmåte for fremstilling av substituerte piperidiner
IT1235026B (it) Apparecchio per la manutenzione di pozzi
FR2640763B1 (fr) Procede de prospection electrosismique
ITTO920136A0 (it) Procedimento di produzione di organopolisilossani
FR2628423B1 (fr) Procede de preparation de sulfates cycliques
FI941046A7 (fi) Farmaseuttinen menetelmä
FR2664274B1 (fr) Procede de preparation de sulfates cycliques.
FI940280L (fi) Menetelmä demetyyliepypodofyylilotoksiinin valmistamiseksi
FI921523A7 (fi) Menetelmä ginkgolidi B:n valmistamiseksi ginkgolidi C:stä
IT9020580A0 (it) procedimento per la produzione
FI912868A7 (fi) Menetelmä farmaseuttisten yhdisteiden valmistamiseksi
MA22401A1 (fr) Procede de preparation de sels de guinoleine
FI933057A7 (fi) Klorfri process foer blekning av lignocellulosahaltig pappersmassa
DK0512652T3 (da) Hydrodecykliseringsfremgangsmåde
FI933755A7 (fi) Menetelmä trans-piperidiini-2,5-dikarboksylaattien valmistamiseksi
FI912626A7 (fi) Menetelmä B-hydroksi-a-aminohappojen valmistamiseksi
FR2626883B1 (fr) Procede de preparation de n-phosphonomethyl-imino-diacetique
FI922722L (fi) Process foer aotervinning av icke-jaernhaltiga metaller fraon pyritslagg
IT1226380B (it) Dispositivo per la produzione di filati